Acute myeloid leukemia in the real world: why population-based registries are needed. - Wikidata - wikimedia - TriplyDB

Acute myeloid leukemia in the real world: why population-based registries are needed.

Acute myeloid leukemia in the real world: why population-based registries are needed.

http://www.wikidata.org/entity/Q35980291

about

Post-remission therapy for acute myeloid leukemia RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs Acute myeloid leukaemia: challenges and real world data from India Data quality in the Danish National Acute Leukemia Registry: a hematological data resource Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Easily manageable prognostic factors in 152 Chinese elderly acute myeloid leukemia patients: a single-center retrospective study.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cells Management of older or unfit patients with acute myeloid leukemia Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.The benefit of population-based studies for older patients with acute myeloid leukemia Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines.Physician's Attitude Towards Treatment of Older Patients and the Choice of Therapy Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience.Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Acute myeloid leukemia in the elderly: do we know who should be treated and how?Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Review of 103 Swedish Healthcare Quality Registries.Epidemiology of chronic myeloid leukaemia: an update.Elderly acute myeloid leukemia: assessing risk.Chemotherapy options for previously untreated acute myeloid leukemia.Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort study Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.Aging: Treating the Older Patient.PD-1 signaling and inhibition in AML and MDS.Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.

P2860

Q26995867-CF16F6B1-9003-4ECA-B41A-EFD357DE81AA Q27853381-82C81E25-D21A-4910-B33A-FF08C4E08EC0 Q28071427-50F7BD87-6FEF-4A3B-A38F-9C17502785D5 Q28602934-4B7C9CB4-EDFD-4FC0-8EA3-9698862C5B53 Q30667157-0C703AAC-FCA8-44E7-915C-9A5E02250C81 Q31163049-21EC9CCC-888F-4E13-9ADA-36403518A3EB Q31169518-BF555ACA-478D-43B7-8EFE-66EE8F6A260B Q33431584-16BC687B-B4F5-4496-878B-2F115B156B4E Q34340772-65C5B8F5-D83C-4333-9286-E8908021D388 Q34428556-9ADA88E5-B988-4BF5-8582-D52126DEE8CF Q34527239-C895E809-2B7F-4DE8-A45E-3031184AB36D Q34703798-99169F32-3CAB-4966-8EC6-ECA164B1582C Q34893307-A4D8BF24-0880-496F-8A22-EA06278159C1 Q36597388-A33A6C3F-B5D8-4E53-AC2F-04443118E826 Q36618933-C29D58B3-F655-4B41-9096-CB40DE16A627 Q36662009-5F5F31CD-153A-451C-828C-112DFF07253F Q36723291-E5AA16DB-EEDB-41A8-9502-6211A95BDE43 Q36753274-E38C3E91-7358-425E-AD40-A34F690F5386 Q36826175-7C10D14D-1724-40DB-ADFC-C6A734AE4ADB Q36828419-2E912F94-C01B-4A77-AD7A-49F3E4298D03 Q36934395-CA3D07EC-7E81-43AF-B8CD-A31B0AE4FA9A Q37098856-BE8AA781-30BB-4CB8-BA9E-B8D9B70760EE Q37605585-0C38E62F-45BB-45E9-8327-17C1FD010AA8 Q37621352-44B4B374-3D65-4626-A292-FBC8580EA911 Q37683373-A0DB84BD-8A47-4601-BFCF-0122CA4A1A40 Q38091393-900149B9-4E5D-4C3C-8066-EE511550B703 Q38104287-1DDB0520-83B5-466D-91D7-73C2F6738289 Q38124066-3446B9BA-837A-42E5-8940-18E0E6472333 Q38161965-9474C947-1A25-44F4-BFC0-5D7460542FF0 Q38244987-700AE4CD-AB92-476C-9F95-D1BE2167CE9D Q38392709-6E983AA0-F9F1-4FD4-9A02-33C989E5438E Q38458166-A43C0DFE-F5FB-4D84-8E55-777BD6F3B666 Q38585930-EEC6BB29-64FB-4892-B59D-A7BA0C784473 Q38614756-61196530-52AB-4EBC-807D-62D65BF93BE5 Q38642912-ABB5571B-4157-4289-A91B-DB1DB85ED6AA Q38832223-98234AC2-5E30-465F-871B-DFE35C596105 Q38967020-FC18A248-FB07-4653-89D4-28615010E8D6 Q39013605-439A19EA-DE64-4997-BACB-78365F7171F7 Q39393084-17C1B7FE-CB0D-4208-94F3-45691EE8EE7D Q40138696-A68FE715-7A52-4E27-8787-CFFEEF96376A

P2860

Acute myeloid leukemia in the real world: why population-based registries are needed.

http://www.wikidata.org/entity/Q35980291

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Acute myeloid leukemia in the real world: why population-based registries are needed.

@ast

Acute myeloid leukemia in the real world: why population-based registries are needed.

@en

type

label

Acute myeloid leukemia in the real world: why population-based registries are needed.

@ast

Acute myeloid leukemia in the real world: why population-based registries are needed.

@en

prefLabel

Acute myeloid leukemia in the real world: why population-based registries are needed.

@ast

Acute myeloid leukemia in the real world: why population-based registries are needed.

@en

P1433

Q35980291-95D8C5C4-B26D-4DFB-AA32-74C08A724628

P1476

Q35980291-BDD55650-424D-43CB-AF70-8E22971ABAFC

P2093

Q35980291-15B02DFC-2EB9-4FC8-A03B-A0AE6B1F5576

Q35980291-29A17A7C-372E-4B0D-A8DC-6C624FEEF206

Q35980291-8DD006C9-3C01-4F16-83E5-A3C4AF87B6B1

Q35980291-BC95F1BC-C7BB-47B6-8698-7566E3AC4419

Q35980291-C24FEAF4-3700-41F9-81C8-22C4106D05D5

Q35980291-DA569C50-6A0C-4E48-81CD-DAB923FFC3AE

P2860

Q35980291-001D4B2F-2212-4009-A2C8-BCD5601AC02E

Q35980291-015149F3-CE32-4906-9B97-FC2DC1CA30FF

Q35980291-04B29E81-A3C3-400C-8425-319721FF78B4

Q35980291-09E096AC-10C0-4ECF-9BCD-668E2F3BBCF0

Q35980291-0CF276B6-9D5B-477A-AF4D-7FD4E0D531E0

Q35980291-0D7A4E42-91E7-4B4E-85EB-5B27DAA5925F

Q35980291-138DEC76-9A95-492D-9FCE-08ECBB73FAF1

Q35980291-142F7320-03E5-4FDF-B8B3-87D66F7852CE

Q35980291-14F40886-F791-46AE-8FCD-2C79C6F3D1F2

Q35980291-2180A19A-7116-4ABD-8557-2C5153C51B81

P304

Q35980291-11BE3974-E6CD-45DC-AFEB-1D4D94084B88

P31

Q35980291-E424B890-5150-4582-AA1B-48DED44D536C

P356

Q35980291-B7E6813D-4D2F-4113-A750-9CA23C0FBED9

P407

Q35980291-47F0B8B9-727A-4E6A-B5A1-C16A201AD2C0

P433

Q35980291-82C2F80E-D330-4AB4-A9E9-67647947C738

P478

Q35980291-C6559A09-F4F5-416F-BD5A-CEC6F5C5D136

P577

Q35980291-A02564BC-11AA-4944-AE9C-7129E323BAB0

P5875

Q35980291-31FE47D9-684B-470F-8012-E0D64810CCE5

P698

Q35980291-F6D3447A-9987-4229-9E7F-1B9DCAE758E3

P921

Q35980291-86B6EF9D-7174-4279-900D-953590BB2131

P932

Q35980291-75CEA631-C89B-4505-AF1B-577014669A41

P356

BLOOD-2011-12-379008

P1433

P1476

Acute myeloid leukemia in the real world: why population-based registries are needed.

@en

P2093

Ann-Sofi Hörstedt

http://www.w3.org/2001/XMLSchema#string

Gunnar Juliusson

http://www.w3.org/2001/XMLSchema#string

Martin Höglund

http://www.w3.org/2001/XMLSchema#string

Oskar Hagberg

http://www.w3.org/2001/XMLSchema#string

Swedish Acute Leukemia Registry Group

http://www.w3.org/2001/XMLSchema#string

Vladimir Lazarevic

http://www.w3.org/2001/XMLSchema#string

P2860

Grading quality of evidence and strength of recommendations

Evidence based medicine: what it is and what it isn't

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Cancer statistics, 2007

The incidence of and mortality from leukaemias in the UK: a general population-based study

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study

Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.

Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data.

P304

3890-3899

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-12-379008

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221882403

http://www.w3.org/2001/XMLSchema#string

P698

22383796

http://www.w3.org/2001/XMLSchema#string

P921

P932

3358248

http://www.w3.org/2001/XMLSchema#string